Stock DNA
Pharmaceuticals & Biotechnology
CAD 56 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-2.13
98.35%
-0.30
Revenue and Profits:
Net Sales:
120 Million
(Quarterly Results - Jun 2025)
Net Profit:
-107 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-46.67%
0%
-46.67%
6 Months
-68.0%
0%
-68.0%
1 Year
-85.96%
0%
-85.96%
2 Years
-93.85%
0%
-93.85%
3 Years
-98.14%
0%
-98.14%
4 Years
-99.41%
0%
-99.41%
5 Years
-98.94%
0%
-98.94%
The Cannabist Company Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
31.84%
EBIT Growth (5y)
9.45%
EBIT to Interest (avg)
-2.86
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-4.87
Sales to Capital Employed (avg)
1.41
Tax Ratio
50.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.37
EV to EBIT
-8.20
EV to EBITDA
-116.09
EV to Capital Employed
2.21
EV to Sales
0.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.99%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Bearish
Bearish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 8 Foreign Institutions (0.06%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
119.50
125.50
-4.78%
Operating Profit (PBDIT) excl Other Income
-10.60
1.00
-1,160.00%
Interest
21.30
14.20
50.00%
Exceptional Items
0.70
-12.50
105.60%
Consolidate Net Profit
-107.10
-46.20
-131.82%
Operating Profit Margin (Excl OI)
-183.40%
-91.10%
-9.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -4.78% vs -6.62% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -131.82% vs 40.08% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
628.40
690.10
-8.94%
Operating Profit (PBDIT) excl Other Income
39.60
58.20
-31.96%
Interest
56.80
74.10
-23.35%
Exceptional Items
-44.80
-122.70
63.49%
Consolidate Net Profit
-144.00
-235.20
38.78%
Operating Profit Margin (Excl OI)
-43.70%
-38.40%
-0.53%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -8.94% vs 3.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 38.78% vs 57.14% in Dec 2023
About The Cannabist Company Holdings, Inc. 
The Cannabist Company Holdings, Inc.
Pharmaceuticals & Biotechnology
Columbia Care Inc is a provider of cannabis-based health and wellness solutions. The Company is engaged cultivating, manufacturing and providing medical and adult use cannabis products and related services with licenses in over 18 the United States jurisdictions and the European Union (EU). The Company operates over 108 facilities including 81 dispensaries and 27 cultivation and manufacturing facilities. The Company operates as the original providers of medical cannabis in the United States and continues to deliver a patient-centered medicinal cannabis operation. The company offers products spanning flower, edibles, oils, and tablets, and manufactures brands including Seed & Strain, Amber and Platinum Label Cannabidiol (CBD) products.
Company Coordinates 
Company Details
680 Fifth Ave., 24th Floor , NEW YORK NY : 10019
Registrar Details






